Volume 134 Issue 26 | Blood | American Society of Hematology
Read the current issue of Blood.
Related Articles
Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia
Valentin Goede, Kirsten Fischer, Sandra Robrecht, Adam Giza, Martin JS Dyer, Michael J. Eckart, Lothar Müller, Lukáš Smolej, Nadine Kutsch, Anna-Maria Fink
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
Key PointsVenetoclax (14 days) + azacitidine regimen was well tolerated in patients with treatment-naive HR MDS, with no unexpected safety findings.The reg
Selenoprotein-mediated redox regulation shapes the cell fate of HSCs and mature lineages
Key PointsDisruption of antioxidant selenoprotein synthesis exhibited significant defects in B lymphocyte development and HSC function.Cell context and lin
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement
Key PointsB-cell maturation antigen–directed CAR-T therapy in patients with MM and CNS involvement is feasible without excess neurotoxicity.Data support CN
Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML
Key PointsDetection of mNPM1 MRD by NGS using DNA overcomes several limitations of RT-qPCR and is therefore an attractive alternative assay.The prognostic
The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma
Key PointsLenalidomide induces immunomodulating responses through the activation of dsRNA-sensing pathway.ADAR1 drives lenalidomide resistance in MM via th
α-Actinin-1 deficiency in megakaryocytes causes low platelet count, platelet dysfunction, and mitochondrial impairment
Key Pointsα-Actinin-1 deficiency in MKs is associated with low platelet count and leads to impaired platelet function and thrombosis.α-Actinin-1 is critica
Targeting senescent stemlike subpopulations in Philadelphia chromosome–like acute lymphoblastic leukemia
Key PointsOur study discovered new regulators of ruxolitinib response in Ph-like ALL, including c-MYC as a therapeutically targetable codependency.A progno
Unbiased high-throughput screening of drug-repurposing libraries identifies small-molecule inhibitors of clot retraction
Key PointsWe developed of a high-throughput screening assay to identify small-molecule inhibitors of fibrin-mediated clot retraction.Screening 9710 compoun
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts
Abstract. Measurable residual disease (MRD) is a powerful predictor of clinical outcomes in acute lymphoblastic leukemia (ALL). In addition to its clear pr
